We are pleased to announce that we will be participating in the ECTS Congress 2022 in Helsinki. We will sponsor an Education Symposium and the European Rare Bone Forum General Meeting will also take place during the event.
On Jan 24, Ipsen announced the Canada approval of Sohonos (palovarotene). Indicated to reduce new bone formation in adults and children with FOP. Sohonos is approved for both chronic use, and for flare-ups. It is the first approval for Sohonos worldwide.
Please join us on Thursday October 29, 2020 15h CET. Julia Quitmann (University Medical Center, Hamburg – Eppendorf) will be our Speaker addressing Quality of Life Studies in Rare Bone Diseases: why, who and how? This Webinar has the support of the European Calcified Tissue Society (ECTS).